Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|September 19, 2021
Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell TransplantationNicholas A Szewczyk, An Ngo-Huang, Tacara N Soones, et al.
Blood Advances|December 11, 2019
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantationLi Li, Han Chen, David Marin, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2026
Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T CellsAmanda Olson, Ye Li, David Marin, et al.
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2020
Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|September 19, 2021
Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell TransplantationNicholas A Szewczyk, An Ngo-Huang, Tacara N Soones, et al.
Blood Advances|December 11, 2019
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantationLi Li, Han Chen, David Marin, et al.
Transplantation and Cellular Therapy|July 30, 2021
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical TrialRohtesh S Mehta, Roland Bassett, Julianne Chen, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2026
Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T CellsAmanda Olson, Ye Li, David Marin, et al.
Blood Advances|April 3, 2020
Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entityAnkur Varma, Susan C Abraham, Rohtesh S Mehta, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Blood Advances|August 23, 2023
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbiditiesUday R Popat, Oren Pasvolsky, Roland Bassett, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2020
Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapyRafet Basar, Nadima Uprety, Emily Ensley, et al.
Cancer|July 13, 2016
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationSameh Gaballa, Isabell Ge, Riad El Fakih, et al.
Pageof 18